Literature DB >> 11592110

Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis.

R Stanislaus1, A K Singh, I Singh.   

Abstract

Mononuclear cell infiltration into the CNS and induction of inflammatory cytokines and iNOS in diseases like multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE) have been implicated in subsequent disease pathogenesis and progression. We report that Lovastatin treatment blocks the clinical disease and induction of inflammatory cytokines and iNOS in spinal cords of MBP induced EAE rats. A significant number of the infiltrating cells in CNS were ED1+ cells of monocyte/macrophage lineage. To understand the mechanism of efficacy of Lovastatin against EAE, we examined the effect of Lovastatin on the transmigration of mononuclear cells into EAE spinal cord. The data presented here documents that Lovastatin treatment attenuates the transmigration of mononuclear cells possibly by down regulating the expression of LFA-1, a ligand for ICAM, in endothelial-leukocyte interaction. These results indicate that Lovastatin treatment prevents infiltration by mononuclear cells into the CNS of rats induced for EAE, thereby lessening the histological changes and clinical signs and thus ameliorating the disease. These observations indicate that Lovastatin treatment may be of therapeutic value against inflammatory disease process associated with infiltration of activated mononuclear cells into the tissue. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592110     DOI: 10.1002/jnr.1207

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  40 in total

Review 1.  Statins for multiple sclerosis.

Authors:  Jin Wang; Yousheng Xiao; Man Luo; Hongye Luo
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 3.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 4.  Combination therapies in multiple sclerosis.

Authors:  Ralf Gold
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

5.  Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Authors:  James A Carroll; Brent Race; Katie Phillips; James F Striebel; Bruce Chesebro
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

6.  Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells.

Authors:  Meenakshi Arora; Li Chen; Melissa Paglia; Iain Gallagher; Judith E Allen; Yatin M Vyas; Anuradha Ray; Prabir Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

7.  Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Inderjit Singh; Avtar K Singh
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 8.  [Statins for treatment of CNS diseases. Status report from research and clinical practice].

Authors:  T Menge; H-C von Büdingen; S S Zamvil; H-P Hartung; B C Kieseier; O Stüve
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

9.  Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death.

Authors:  Jin-Koo Lee; Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  Neurosci Lett       Date:  2008-06-06       Impact factor: 3.046

10.  SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Authors:  Christian P Kamm; Heinrich P Mattle
Journal:  Trials       Date:  2009-12-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.